1 ons; of those, 54 patients were eligible and
assessable.
2 ach specific cytogenetic abnormality was not
assessable.
3 Data from 5,171 patients were
assessable.
4 tal of 30 patients were enrolled and 28 were
assessable.
5 Three patients (6%) were not
assessable.
6 rty-nine patients (25 with M1c disease) were
assessable.
7 A total of 644 patients were
assessable.
8 195; BCT, n = 200) were deemed eligible and
assessable.
9 atients; thus, 140 patients in each arm were
assessable.
10 One died within 72 hours and was not
assessable.
11 There were 26 patients enrolled; 18 were
assessable.
12 219 of 227 enrolled patients were
assessable.
13 3) had at least 1 subcompetency rated as not
assessable.
14 219 of these 227 enrolled patients were
assessable.
15 1,551 randomly assigned patients, 1,524 were
assessable.
16 Forty-nine patients were entered and 43 were
assessable (
12% stage IB; 37% stage II; and 52% stage II
17 tients who underwent randomisation, 217 were
assessable 2 h after the start of acetylcysteine treatme
18 A total of 651 patients were
assessable (
227 randomly assigned to tamoxifen and 424 r
19 immunoreactivity in primary NENs is readily
assessable and a potentially useful stage-independent pr
20 Of 682 patients enrolled, 644 patients were
assessable and analyzed.
21 nts had no PSA response and 6 (15%) were not
assessable and assumed to be nonresponders.
22 Tissue was
assessable and ER and/or PgR positivity confirmed centra
23 ntle cell lymphoma were enrolled and 69 were
assessable and were included in the final analysis.
24 (63.1%, 60.3-65.8) of 1211 patients who were
assessable,
and adverse events curtailed treatment in 12
25 and 7, at least 12 patients per cohort were
assessable,
and the dose level with prospectively define
26 100% histologic cure was achieved in 9 of 9
assessable animals without detectable radiation damage t
27 More than 90% of 26
assessable archival tumor specimens were highly positive
28 (arm A, n = 41; arm B, n = 43), and 72 were
assessable (
arm A, n = 37; arm B, n = 35).
29 of patients assigned erlotinib and who were
assessable at 1 month developed first-cycle rash, which
30 d 132 (31%) patients, respectively, were not
assessable at 2 months and were counted as missing data
31 F and survival were compared in 135 patients
assessable at 2 months with tumor shrinkage below (poor
32 One hundred sixteen patients were
assessable at 3 months postoperatively.
33 and Human Development to relate risk factors
assessable at or before birth to the likelihood of survi
34 95% CI 21.4-26.2) of 1241 patients who were
assessable at week 14.
35 one individual with thymic carcinoma was not
assessable because she died.
36 ells to similar extents, providing an easily
assessable biomarker of anti-GITR activity.
37 A rapidly
assessable biomarker of chromosomal instability in CTC i
38 we identified 55,038 adults with sepsis and
assessable body mass index measurements: 6% underweight,
39 No examination was considered as not
assessable but 6% (3/50) were scored as adequate for dia
40 ted ascending aortic geometries that are not
assessable by current echocardiographic measures.
41 ed C1 and C2, respectively) and were MFC-MRD
assessable by LAIP detection in CR bone marrow for at le
42 Of nine patients
assessable by PET,responses were complete in five patien
43 acteristics and patient-related risk factors
assessable by the clinician at patient presentation can
44 ic modifications of mucus contrasts that are
assessable by using a noninvasive, contrast material-fre
45 Of the 26 measures, 10 are readily
assessable by using cancer registry data.
46 ee hundred eighty-five patients patients had
assessable CA 19-9 levels.
47 Of 910 total
assessable cases, 112 of 488 ErbB-2-positive cases (23%)
48 Effusions were exudative in 78% of the
assessable cases.
49 xclusively based on objective preoperatively
assessable characteristics and can be rapidly and easily
50 Of 294/315
assessable children, 15/294 had pure spasticity, leaving
51 ry tumour samples, of whom 865 (50%) had two
assessable cores (445 in the control groups and 420 in t
52 seen in 51 of 73 patients and in 107 of 209
assessable coronary arteries.
53 The percentage of
assessable coronary artery segments was 98.6% (1196 of 1
54 er D-serine (n=20) or placebo (n=24); 35 had
assessable data (15 D-serine, 20 placebo).
55 ble patients were enrolled, of whom 1941 had
assessable data (968 in the capecitabine alone group and
56 y and either gefitinib or erlotinib, and had
assessable disease (RECIST 1.1) and tumour tissue sample
57 Ten of 46 patients with
assessable disease had a partial response, and these res
58 ne included FOLFOX4 treatment, patients with
assessable disease, or a single site of metastasis.
59 y Group performance status of 2 or less; had
assessable disease; were not suitable to receive any est
60 (93%) entered PEOPLE, of whom 141 (71%) had
assessable double-blind, placebo-controlled food challen
61 CU days of observation in which delirium was
assessable (
e.g., patient was noncomatose), with a total
62 NSCLC), and that this determination might be
assessable early on during therapy.
63 -treat analysis, 82 of 345 patients with the
assessable end point were reoperated for positive or clo
64 ing only the per-protocol population with an
assessable end point, the difference was 9% (stratified
65 The proportions of patients having
assessable EORTC QLQ-C30 and EQ-5D questionnaires at bas
66 published primary outcome with 90% of those
assessable favoring a statistically positive result.
67 CTP was available and
assessable for 591 (34%) patients and diffusion MRI for
68 Among 33 patients
assessable for a cytogenetic response, 17 (52%) experien
69 All treated patients were
assessable for a response.
70 led and given cabozantinib; 25 patients were
assessable for a response.
71 he cutoff date of Aug 11, 2018, 101 patients
assessable for activity in phase 2 were followed up for
72 s in the methotrexate-vinblastine group were
assessable for activity.
73 prised the full analysis set and were deemed
assessable for activity.
74 ylphenidate and 53 in the placebo group were
assessable for analysis.
75 50 patients were
assessable for both toxic effects and response; eight ad
76 erapy for at least 1 year, 173 patients were
assessable for cardiac toxicity.
77 30 patients were
assessable for change in lean body mass, which increased
78 Of the 12 patients who were
assessable for chemotherapeutic response (pre-RT), the o
79 Of 104 patients recruited, 100 patients were
assessable for clinical benefit prior to planned nephrec
80 Of 42 patients enrolled, 39 were
assessable for clinical outcome and DC analysis.
81 Of 43 patients
assessable for clinical response, two patients had confi
82 Among 73 patients
assessable for clonal evolution during stable chronic ph
83 ten in the safety expansion group); 31 were
assessable for efficacy (<400 mg, n=16; 400 mg, n=15).
84 and 42 (93%) patients with osteosarcoma were
assessable for efficacy after histological and radiologi
85 A total of 133 patients were
assessable for efficacy and safety.
86 for 5 days and 43 for 10 days, and all were
assessable for efficacy and safety.
87 All patients were
assessable for efficacy and safety.
88 Sixteen of 23 patients
assessable for efficacy in the nonrandomized single-arm
89 in cohort 1 and 62 patients in cohort 2 were
assessable for efficacy.
90 patients were enrolled and 30 patients were
assessable for efficacy.
91 pezil group and 56 in the placebo group were
assessable for final analysis.
92 to treatment in the CLARITY study, 1192 were
assessable for freedom from disease activity at 96 weeks
93 f treatment received but restricted to those
assessable for hearing loss.
94 hs of radiographic follow-up were considered
assessable for local control.
95 Forty-nine discrete lesions were
assessable for local control.
96 Fifty lesions were
assessable for local control.
97 enty-one patients were included, and 19 were
assessable for metabolic response evaluation with FLT-PE
98 Forty-seven patients
assessable for PN received a median of five cycles of th
99 ved 400 mg, and 33 who received 1400 mg were
assessable for PSA response at 12 weeks.
100 However, among 40 patients
assessable for radiologic response, none experienced par
101 242 patients enrolled, 224 were eligible and
assessable for response (106 and 118 patients in the con
102 Forty-three enrolled patients were
assessable for response and safety.
103 34/216) and 8% (18/214) of patients who were
assessable for response in these respective groups had a
104 Of 19 patients treated for refractory NB and
assessable for response, nine showed evidence of disease
105 Of 161 patients
assessable for response, one patient with hepatoblastoma
106 Among the 49 patients
assessable for response, the objective response rate was
107 ents assessable for toxicity and 20 patients
assessable for response.
108 Thirty patients were
assessable for response.
109 ) had progressive disease, and five were not
assessable for response.
110 nsformed (20%) disease were treated; 74 were
assessable for response.
111 al of 126 patients were treated and 113 were
assessable for response.
112 were enrolled; 27 were eligible, and 26 were
assessable for response.
113 ctory myeloma were enrolled, 34 of whom were
assessable for response.
114 tients were entered onto the study, with 103
assessable for response.
115 52 (48%) of 108 patients
assessable for safety in phases 1 and 2 had grade 3 or w
116 Of the 47 patients
assessable for safety, grade 3 or 4 hematologic events w
117 atients, 48 underwent two MRIs; 44 MRIs were
assessable for study end points.
118 Four hundred four patients were
assessable for surgical outcomes.
119 Of these, 104 participants were
assessable for the primary endpoint (sodium thiosulfate,
120 In the first 43 patients
assessable for the primary endpoint in the pazopanib gro
121 We deemed patients as
assessable for the primary endpoint in the phase 1 porti
122 175 (79%) participants were
assessable for the primary outcome in the mITT populatio
123 A total of 230 patients were
assessable for this analysis: 99 patients with severe la
124 -non-amplified disease; 55 patients were not
assessable for TOP2A status.
125 Dec 31, 2015, 23 patients were enrolled and
assessable for toxic effects after completing accrual.
126 the study at levels 1 to 4, with 18 patients
assessable for toxicity and 20 patients assessable for r
127 toma and no prior ASCT were entered; 22 were
assessable for toxicity and response.
128 icity) or 260 mg/m2/d (seven enrolled, three
assessable for toxicity) of temozolomide.
129 ved either 200 mg/m2/d (nine enrolled, three
assessable for toxicity) or 260 mg/m2/d (seven enrolled,
130 Fifteen patients (12 fully
assessable for toxicity) with first or later CD22-positi
131 21 years), were enrolled, and 42 were fully
assessable for toxicity.
132 , and 18 completed one course and were fully
assessable for toxicity.
133 ere enrolled, and 18 (12 with sarcomas) were
assessable for toxicity.
134 Twenty-three patients were enrolled and
assessable for toxicity.
135 years), were enrolled, of whom 29 were fully
assessable for toxicity.
136 y-three solid tumor and 17 NF1 patients were
assessable for toxicity.
137 one patients were enrolled; 32 patients were
assessable for toxicity.
138 Thirty patients received treatment and were
assessable for toxicity.
139 Five patients were not
assessable for tumor response.
140 48 patients were
assessable for tumour response.
141 patients for whom treatment and outcome were
assessable had full (three patients) or partial (nine pa
142 -modality, and boost therapy, 37 (82%) of 45
assessable high-risk patients achieved a complete respon
143 the surgical ICU; 227 of 415 (55%) long-stay
assessable ICU patients were weak; 122 weak patients wer
144 Patients were
assessable if eligible for the MA.27 trial, received som
145 ive analysis of 372 breast cancer cases with
assessable immunohistochemical data for ER, PR, and Her-
146 The combined end point was
assessable in 155 (97%) patients.
147 Perfusion defects on DECT (
assessable in 18/20 [90%]) were present in all patients
148 y to SEE for functional recovery but was not
assessable in 25% of patients.
149 Treatment effects and outcome were
assessable in 501 (median follow-up 24 months, range 4-1
150 EGFR FISH was
assessable in 76 patients with available tumor tissue an
151 EGFR FISH was
assessable in 976 patients and 400 patients (41%) were E
152 herapeutical consequences but are not easily
assessable in patients.
153 logic conditions but has not been previously
assessable in population cohorts.
154 6%) in the CBT group, whereas 135 (61%) were
assessable in the PP population in the BA group compared
155 status epilepticus was 35 min (IQR 20 to not
assessable)
in the levetiracetam group and 45 min (24 to
156 he levetiracetam group and 45 min (24 to not
assessable)
in the phenytoin group (hazard ratio 1.20, 9
157 A rating of "not
assessable"
indicated insufficient information to evalua
158 Median follow-up for
assessable lesions was 15.4 months (range, 6 to 48 month
159 Median follow-up for
assessable lesions was 16 months (range, 6 to 54 months)
160 in 21/33 (63.6%) patients with at least two
assessable lobes (including 10/21 [47.6%] with no eviden
161 acy analysis population (patients with fully
assessable locally advanced disease and all those with m
162 primary analysis (PA) and the microbiologic
assessable (
MA) populations.
163 All 15
assessable margins were clear on CLI and histopathology.
164 Overall, 303
assessable men were randomly assigned to C-IMRT or H-IMR
165 To identify a powerful and easily
assessable miRNA bio-marker of prognosis and survival, w
166 patients where radial margin status was not
assessable (
n = 16).
167 for which the status of the choroid was not
assessable (
n = 35) were excluded.
168 ressive disease (PD), and seven patients not
assessable (
NA).
169 ble disease (SD) for 8 or more courses in 30
assessable neuroblastoma patients.
170 the new sensor array was tested for an easy
assessable objective: coffee ageing during storage.
171 neteen of 122 randomly assigned patients had
assessable outcomes.
172 A total of 136 eligible and
assessable patients (101 untreated, 35 previously treate
173 ith GBM (95% CI, 0.1% to 15%) and five of 32
assessable patients (16%) with anaplastic glioma (95% CI
174 73.9) in the capecitabine group and 18 of 35
assessable patients (51.4%, 39.4-63.4) in the gemcitabin
175 After 9 months, 22 of 35
assessable patients (62.9%, 80% CI 50.6-73.9) in the cap
176 Four of six
assessable patients (67%) with DLBCL achieved an OR, inc
177 Responses were observed in five of six
assessable patients (83%) at the MTD.
178 urable responses were seen in 19 (76%) of 25
assessable patients (95% exact binomial CI, 55% to 91%),
179 Between 1987 and 1991, 456
assessable patients (median age, 70 years) were enrolled
180 ot complete the cognitive screen, leaving 85
assessable patients (median age, 72 years).
181 Of 13
assessable patients (nine with adult T-cell leukaemia-ly
182 rtial responses seen in seven of 25 response-
assessable patients (overall response 28%, 95% CI 12-49)
183 Twenty-three (49%) of 47
assessable patients achieved a complete response (CR) to
184 Twelve (19%) of 62
assessable patients achieved an objective confirmed resp
185 In untreated AML, four of nine
assessable patients achieved CR.
186 Three of 13
assessable patients achieved objective radiographic and/
187 Pseudoprogression was observed in 37% of
assessable patients and may have had an impact on estima
188 In phase II, 8 (10%) of 84 response-
assessable patients attained objective antitumor respons
189 All
assessable patients engrafted, with median time for neut
190 11 (18%) of 60
assessable patients had a confirmed objective response,
191 or 0.4 mg/kg every 6 weeks), 11 (18%) of 60
assessable patients had a confirmed objective response.
192 te toxicities and 131 controls; thus, 43% of
assessable patients had a severe late toxicity.
193 Six of 22
assessable patients had complete or partial response, an
194 Nine (20%) of 46
assessable patients had confirmed partial responses unti
195 sistant neuroblastoma, and seven (50%) of 14
assessable patients had response or disease stabilizatio
196 sponses were needed in the first 20 response-
assessable patients in each of the five tumour cohorts.
197 red orally daily to groups of at least three
assessable patients in escalating doses of 50, 75, 100,
198 An interim analysis of the first 23
assessable patients in the first cohort treated at 420 m
199 31 (76%) of 41
assessable patients in the fluorouracil group had grade
200 34 (85%) of 40
assessable patients in the paclitaxel group had grade 3-
201 Prognostic factors in
assessable patients included advanced stage (III/IV) in
202 Ninety-nine
assessable patients received 6 cycles of doxorubicin 25
203 Fourteen
assessable patients received 75 courses.
204 Fifty-four
assessable patients received paclitaxel consolidation.
205 Forty-five
assessable patients received protocol therapy.
206 Treatment of six
assessable patients resulted in one venous thrombosis; t
207 d 10.6 +/- 4.4 months, with nine of 16 (56%)
assessable patients surviving 1 year or longer.
208 For the 146
assessable patients treated with bexarotene, median age
209 edian follow-up time, the overall RR for 121
assessable patients was 16.5% (95% CI, 10% to 26%); the
210 dian age at the time of follow-up for the 20
assessable patients was 16.9 years (IQR 15.5-21.8).
211 The 5-year survival rate of the 76
assessable patients was 24% (median, 20 months).
212 The pCR rate for all
assessable patients was 26% in each arm.
213 Response rate in 141
assessable patients was 33% including 8% complete respon
214 an follow-up time for all 1,236 eligible and
assessable patients was 35.7 months.
215 The overall response rate for the 130
assessable patients was 39% (chemotherapy, 34%; chemoimm
216 The distribution of
assessable patients was: two of three in cohort 1, three
217 he response rate and disease control rate in
assessable patients were 36% and 82%, respectively.
218 ion (CR2) rates at the end of block 1 in 117
assessable patients were 68% +/- 6% for ER (n = 63) and
219 Six hundred nineteen
assessable patients were analyzed.
220 5% confirmed overall response rate (ORR), 41
assessable patients were needed.
221 A total of 76
assessable patients were treated on this phase II trial,
222 Seventeen
assessable patients were treated.
223 Of the six
assessable patients who had declined the procedure, one
224 Of the 14
assessable patients who had successfully undergone ovari
225 tients who received 8 Gy vs 229 [66%] of 349
assessable patients who received 20 Gy; p=0.011) and dia
226 Two of six
assessable patients who received 56 mg/m(2) had reversib
227 days were lack of appetite (201 [56%] of 358
assessable patients who received 8 Gy vs 229 [66%] of 34
228 There were 303
assessable patients with a median follow-up of 68.4 mont
229 Of 11
assessable patients with AHWT, two had PR, one had SD, a
230 (arm A) or without oblimersen (arm B) in 56
assessable patients with chemotherapy-naive ES-SCLC.
231 Of 25
assessable patients with FHWT, 12 had partial response (
232 on cohorts, 16 (33%, 95% CI 20.4-48.4) of 48
assessable patients with HER2-positive breast cancer ach
233 Between June 7, 2000, and Oct 24, 2007, 498
assessable patients with newly diagnosed ALL were enroll
234 Results One hundred eighty-five
assessable patients with one of 10 subtypes of sarcoma w
235 15.4 months (IQR 13.7-17.3), 89 (82%) of 108
assessable patients with refractory large B-cell lymphom
236 A total of 1,003
assessable patients with SLN metastasis had immediate (n
237 EFS) and overall survival (OS) estimates for
assessable patients with stage I AH (n = 29) were 69.5%
238 Of 23
assessable patients with thymic carcinoma, six (26%, 90%
239 Thirty-one
assessable patients with uveal melanoma demonstrated two
240 [CR] and 13 partial responses [PR] among 44
assessable patients).
241 For 23
assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had
242 Of 21
assessable patients, 11 (52%) responded: four with morph
243 Of the 23
assessable patients, 16 had stable disease as their best
244 In 68
assessable patients, 17 (25%) had grade 3 to 4 esophagit
245 Of 29
assessable patients, 22 were available for PK-based main
246 Of 83
assessable patients, 46 (55%, 95% CI 44-66) achieved a s
247 Of the 56
assessable patients, 48 underwent two MRIs; 44 MRIs were
248 Of the 76
assessable patients, 74 patients (97%) suffered grade 3
249 Focusing on the 61 late-stage (IIIB and IV)
assessable patients, a 15% partial response rate was ach
250 Among response-
assessable patients, an objective response was noted in
251 Of 16
assessable patients, best tumor responses observed were
252 Of 30 efficacy-
assessable patients, five had stable disease (SD) for at
253 The study consisted of 62 eligible and
assessable patients, median age 57 years, 41 (66.1%) hav
254 For 42
assessable patients, median plasma interleukin-6 concent
255 Among
assessable patients, response rate was 26.0% in cohort 1
256 Among 72
assessable patients, response rates of 65% and 50% were
257 In six (27%) of the 22
assessable patients, the asymptomatic BM responded to sy
258 For
assessable patients, the objective response rate (ORR) w
259 In the initially planned cohort of 100
assessable patients, the objective RR was 4% (95% CI, 1.
260 Of 48
assessable patients, the overall response rate was 31% (
261 achieved in seven (26% [95% CI 11-46]) of 27
assessable patients, with three (11% [2-29]) complete an
262 ifestations was observed in 26 (60.5%) of 43
assessable patients.
263 academic practices consecutively enrolled 89
assessable patients.
264 s (69%) and 23 partial responses (26%) in 90
assessable patients.
265 4 to 22+ months) was seen in 22 (59%) of 37
assessable patients.
266 r dose cohort (3,120 mg) was expanded to six
assessable patients.
267 redetermined recruitment stages of 20 and 40
assessable patients.
268 s 11.5% (95% CI, 6.3% to 18.9%) for response-
assessable patients.
269 mor cells was detected in 29 (81%) of the 36
assessable patients.
270 bjective response rate (RR) in the first 100
assessable patients.
271 a Evaluation in Solid Tumors version 1.1) in
assessable patients; those who received at least one dos
272 Approximately 70% of
assessable peptide bond hydrogens were protected from ex
273 Assessable phenotypes before any antiviral treatment inc
274 In Solid Tumors version 1.1 in the response-
assessable population (ie, patients with measurable dise
275 ecific antiviral therapy in the per-protocol
assessable population.
276 the remaining 379 patients had incompletely
assessable postoperative studies.
277 t severity, provides an objective and easily
assessable predictive parameter.
278 entrations <50 nmol/L consisted of 13 easily
assessable predictors, whereas the model for concentrati
279 There is an urgent need for an easily
assessable preoperative test to predict postoperative li
280 In 14 (78%) of 18 Tg-
assessable PTC patients, Tg declined more than 25%.
281 cians surveyed, 535 (54%) and 378 (62%) were
assessable,
respectively.
282 Analysis of 526
assessable respondents showed a wide variation in manage
283 Moreover, 10 of 11
assessable responders who started therapy with reticulin
284 Early responders (67% of patients with
assessable response) achieved pCR in 35.7% compared with
285 er by fluorescent in situ hybridization (374
assessable samples), EGFR protein expression by immunohi
286 vaccine and who provided at least one valid
assessable serum sample.
287 In the response-
assessable study population (n = 47), which had a median
288 ne resistance was present in 58 (53%) of 113
assessable study sites, spread across most countries tha
289 study vaccination and provided at least one
assessable swab after baseline.
290 Six patients were not
assessable:
three discontinued study drug because of a n
291 ipheral-blood mononuclear cells at the first
assessable time point of G3139 exposure, and in eight of
292 F or RAS mutations were detected in 10 of 26
assessable tumor samples.
293 VEGF-A levels in the 17
assessable tumors were higher than in normal breast tiss
294 Ninety (60%) of 149
assessable tumors were KRAS or BRAF wild type (CAPOX, n
295 46 of 48 enrolled patients were
assessable (
two patients had unconfirmed diagnoses).
296 that included only objective preoperatively
assessable variables was developed using a multivariate
297 Eight independent preoperatively
assessable variables were identified and included in the
298 There were 24 patients, and 18 who were
assessable were enrolled.
299 Pain and sedation were always
assessable with excellent inter-rater reliability (numer
300 Thirty-three patients (31
assessable)
with a median age of 12 years were enrolled.